ELND002 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01318421 (ClinicalTrials.gov)	December 2010	8/3/2011	A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ELND002	Elan Pharmaceuticals	NULL	Terminated	18 Years	65 Years	Both	12	Phase 1	NULL
2	NCT01144351 (ClinicalTrials.gov)	March 2010	9/6/2010	A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ELND002;Drug: Placebo	Elan Pharmaceuticals	NULL	Terminated	18 Years	65 Years	Both	32	Phase 1	United States;Canada